Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia

Abstract

BackgroundThe World Health Organization has set an ambitious goal of eliminating viral hepatitis as a major public health threat by 2030. However, in sub-Saharan Africa, antiviral treatment of chronic hepatitis B (CHB) is virtually unavailable. Herein, we present the 1-year results of a pilot CHB treatment program in Ethiopia.MethodsAt a public hospital in Addis Ababa, CHB patients were treated with tenofovir disoproxil fumarate based on simplified eligibility criteria. Baseline assessment included liver function tests, viral markers, and transient elastography (Fibroscan). Changes in laboratory markers were analyzed using Wilcoxon signed-rank tests. Adherence to therapy was measured by pharmacy refill data.ResultsOut of 1303 patients, 328 (25.2%) fulfilled the treatment criteria and 254 (19.5%) had started tenofovir disoproxil fumarate therapy prior to September 1, 2016. Of the patients who started therapy, 30 (11.8%) died within the first year of follow-up (28 of whom had decompensated cirrhosis), 9 (3.5%) self-stopped treatment, 7 (2.8%) were lost to follow-up, and 4 (1.6%) were transferred out. In patients who completed 12 months of treatment, the median Fibroscan value declined from 12.8 to 10.4 kPa (p < 0.001), 172 of 202 (85.1%) patients with available pharmacy refill data had taken ≥ 95% of their tablets, and 161 of 189 (85.2%) patients with viral load results had suppressed viremia. Virologic failure (≥ 69 IU/mL) at 12 months was associated with high baseline HBV viral load (> 1,000,000 IU/mL; adjusted OR 2.41; 95% CI 1.04–5.55) and suboptimal adherence (< 95%; adjusted OR 3.43, 95% CI 1.33–8.88).ConclusionsThis pilot program demonstrated that antiviral therapy of CHB can be realized in Ethiopia with good clinical and virologic response. Early mortality was high in patients with decompensated cirrhosis, underscoring the need for earlier detection of hepatitis B virus infection and timely initiation of treatment, prior to the development of irreversible complications, in sub-Saharan Africa.Trial registrationNCT02344498 (ClinicalTrials.gov identifier). Registered 16 January 2015.

Potential challenges to sustained viral load suppression in the HIV treatment programme in South Africa: a narrative overview

“…There is increasing exposure to antiretrovirals through pre-exposure and post-exposure prophylaxes in many African communities [ 31 ]. Antiretrovirals are also used in managing pathologies such as HBV [ 32 , 33 ]; and their use as narcotics has been reported [ 34 ]. The detection of drug resistant viruses in non-treated persons is generally assumed to be due to an infection by a resistant virus from an individual on treatment.…”

Introduction of birth dose of hepatitis B virus vaccine to the immunization program in Ethiopia: an economic evaluation

“…Treatment of chronic HBV infection with entecavir consumes more resources as compared to treatment with tenofovir, which might have resulted in a less cost-effective estimate in our analysis [ 44 ]. Due to lack of community-based data on treatment eligibility, we used a study conducted in a hospital setting, which might over represent symptomatic cases [ 20 ]. Third, some aspects of vaccine delivery costs (such as transport and maintenance, cold chain storage and capital costs) were based on estimates from other settings that may not reflect the reality in Ethiopia.…”

“…Individuals who do not require antiviral therapy are considered inactive carriers and CAH are those who fulfill the treatment criteria (irrespective of the HBeAg status). A study in Ethiopia has evaluated treatment eligibility and response to antiviral management of chronic hepatitis B infection [ 20 ]. In this study, among individuals 18–25 years of age with chronic HBV infection, nearly a quarter of patients (25%) were eligible to antiviral treatment (ALT > 80 U/L and viral load > 2000 IU/mL).…”

Mother-to-Child Transmission of Hepatitis B Virus in Ethiopia

“…The patients were a mixture of symptomatic individuals seeking medical attention for overt liver disease and asymptomatic HBsAg positive patients screened at antenatal clinics, blood banks, etc. The clinical and operational aspects of this cohort have been published previously [ 20 , 21 , 22 , 23 ].…”